Literature DB >> 25592376

Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.

Luis Fernando Pinto-Peñaranda1, Vladimir Duque-Caballero, Javier Darío Márquez-Hernández, Carolina Muñoz-Grajales, Carlos Jaime Velásquez-Franco.   

Abstract

The objective of this study is to determine the predictive risk factors of failure to achieve remission within 12 months in a group of patients with proliferative lupus nephritis from Northwestern Colombia. Pragmatic clinical study with retrospective analysis was conducted. We included subjects with systemic lupus erythematosus as defined by the American College of Rheumatology with biopsy-proven nephritis. We assessed 149 patients, with 84 % female. Age at diagnosis of systemic lupus erythematosus is 24.7 years (16-31). The time between diagnosis of lupus erythematosus and proliferative nephritis is 2 months (0-35.5). ISN/RPS 2003 histologic classification types are the following: IV (63.8 %), III (13.4 %), V + III (3.3 %), and V + IV (3.3 %). Activity index is 6.18 ± 4.55 and chronicity index is 1 (0-3). The result of 24-h proteinuria is 2000 mg (667-4770) and baseline creatinine is 0.9 mg/dL (0.7-1.3). Induction therapy includes corticosteroids (100 %), cyclophosphamide (74.1 %), and mycophenolate mofetil (25.9 %). At 12 months, 40.7 % of individuals failed to attain partial or complete remission. Elevated creatinine (p = 0.0001) and 24-h proteinuria greater than 1500 mg (p = 0.0011) were basal predictors of failure to attain partial or complete remission by bivariate analysis. Similar results were obtained in multivariate analysis: Baseline creatinine elevation (OR 3.62, 95 % CI, 1.59-8.23; p = 0.002) and 24-h proteinuria greater than 1500 mg (OR 3.62, 95 % CI, 1.29-10.13; p = 0.014) were independent predictors of failure to achieve partial or complete remission. At 12 months, 40.7 % of patients did not attain partial or complete remission. Baseline elevated creatinine and 24-h proteinuria over 1500 mg were predictors for poor response.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25592376     DOI: 10.1007/s10067-015-2864-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

1.  Predictors of chronic kidney disease in Korean patients with lupus nephritis.

Authors:  Su-Jin Moon; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Sung-Hwan Park; Chul-Soo Cho; Ho-Youn Kim
Journal:  J Rheumatol       Date:  2011-10-01       Impact factor: 4.666

2.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2004-12

3.  Factors associated with poor outcomes in patients with lupus nephritis.

Authors:  G Contreras; V Pardo; C Cely; E Borja; A Hurtado; C De La Cuesta; K Iqbal; O Lenz; A Asif; N Nahar; B Leclerq; C Leon; I Schulman; F Ramirez-Seijas; A Paredes; A Cepero; T Khan; F Pachon; E Tozman; G Barreto; D Hoffman; M Almeida Suarez; J C Busse; M Esquenazi; A Esquenazi; L Garcia Mayol; H Garcia Estrada
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 4.  Prognostic factors in lupus nephritis.

Authors:  C C Mok
Journal:  Lupus       Date:  2005       Impact factor: 2.911

5.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

6.  Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes.

Authors:  C Flower; A Hennis; I R Hambleton; G Nicholson
Journal:  Lupus       Date:  2006       Impact factor: 2.911

7.  Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features.

Authors:  P López; L Mozo; C Gutiérrez; A Suárez
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics".

Authors:  Bernardo A Pons-Estel; Luis J Catoggio; Mario H Cardiel; Enrique R Soriano; Silvana Gentiletti; Antonio R Villa; Isaac Abadi; Francisco Caeiro; Alejandro Alvarellos; Donato Alarcón-Segovia
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

9.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

10.  Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus.

Authors:  M R Arbuckle; J A James; G J Dennis; M V Rubertone; M T McClain; X R Kim; J B Harley
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.